Awen Oncology
Awen Oncology is an early-stage oncology research company focused on discovering cancer-specific therapeutic targets and developing preclinical therapeutic candidates. The organization combines high-throughput cell and molecular biology with computational methods, operates laboratory infrastructure, and engages in academic and industry partnerships to advance its oncology pipelines.
Industries
Nr. of Employees
small (1-50)
Products
Preclinical oncology therapeutic pipelines
A portfolio of preclinical therapeutic programs derived from cancer‑specific target discovery for both common and rare cancers.
Preclinical oncology therapeutic pipelines
A portfolio of preclinical therapeutic programs derived from cancer‑specific target discovery for both common and rare cancers.
Services
Partnerships and collaborations with academic institutes, industry partners, and patient advocacy groups to advance oncology research and therapeutic development.
Partnerships and collaborations with academic institutes, industry partners, and patient advocacy groups to advance oncology research and therapeutic development.
Expertise Areas
- Oncology drug discovery
- Cancer target discovery and validation
- Preclinical candidate development
- Computational target identification
Key Technologies
- High‑throughput cellular assays
- Molecular biology techniques
- Computational biology and bioinformatics
- Target identification and validation
News & Updates
Raised seven‑figure investment to support development of cancer‑specific therapies.
Award to support small‑molecule start‑ups by providing chemistry resources and expertise to accelerate drug discovery.
Recipient of the MediWales Innovation Awards Start‑Up Award (2024).
Completed the Cancer Research UK funded Alderley Park Oncology Development programme as one of the UK’s top six new oncology ventures.
Awarded best emerging start‑up at Biovaria 2023.
Chosen to participate as a primary High Growth partner in the Innovate UK programme.
Raised seven‑figure investment to support development of cancer‑specific therapies.
Award to support small‑molecule start‑ups by providing chemistry resources and expertise to accelerate drug discovery.
Recipient of the MediWales Innovation Awards Start‑Up Award (2024).
Completed the Cancer Research UK funded Alderley Park Oncology Development programme as one of the UK’s top six new oncology ventures.
Awarded best emerging start‑up at Biovaria 2023.
Chosen to participate as a primary High Growth partner in the Innovate UK programme.